Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti... by Arndt Borkhardt, Nan Qin, Stephen T Keir, Darell D Bigner, Allison Cole, Matthias Wölfl, Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Joselyn Cruz-Cruz, Claus M Graef, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf Kahlert, Anja Stefanski, Kai Stühler, Julia Hauer, Thomas Beez, Christiane B Knobbe-Thomsen, Ute Fischer, Jörg Felsberg, Finn K Hansen, Rajeev Vibhakar, Sujatha Venkatraman, Samuel H Cheshier, Guido Reifenberger, Thomas Kurz, Marc Remke, Siddhartha Mitra

“…Furthermore, RNA sequencing revealed nuclear factor-kB (NF-κB) pathway induction as a response to CI-994 treatment, followed by transglutaminase 2 (TGM2) expression, which enhanced inflammatory cytokine secretion. We further show interferon-γ release and cell surface expression of engulfment (‘eat-me’) signals (such as calreticulin). …”
Get full text

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma by Chengcheng Zhang, Linling Wang, Qianzhen Zhang, Junjie Shen, Xia Huang, Meiling Wang, Yi Huang, Jun Chen, Yanmin Xu, Wenxu Zhao, Yanan Qi, Yunyan Li, Yanjiao Ou, Zhi Yang, Cheng Qian

“…The identified optimal scFv, M5A, could be potentially applied in future clinical trials of CAR-T cell therapy targeting CEA-positive carcinoma.…”
Get full text